Pilot Therapeutics Holdings Inc. Stock Analysis PLTT

Pilot Therapeutics Holdings, Inc. engages in the development and production of pharmaceutical products for the treatment of dysfunctional lipid metabolism. The company is headquartered in Winston Salem, North Carolina and currently employs 14 full-time employees. The company went IPO on 2000-04-03. Through lipid profiling and metabolism, the Company has developed a proprietary, lipid and genomic profiling research platform, termed Functional Liponomics. Using Functional Liponomics, the Company is developing novel, branded, therapeutic, pharmaceutical and over-the-counter (OTC) medical food products that are specifically designed to address dysfunctional lipid metabolism in chronic human diseases such as asthma, coronary heart disease, allergic rhinitis, cancer, cystic acne and rheumatoid arthritis. Pilot expects to launch its first product, Airozin, for adults and children regionally in April 2003 and nationally by 2004.